Benztropine (mesylate)

Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects[1][2].

Product Specifications

CAS Number

[132-17-2]

Product Name Alternative

Benzatropine mesylate; Benzotropine mesylate; Benztropine methanesulfonate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dopamine Receptor; Histamine Receptor; mAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Benztropine-mesylate.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

CN1[C@H]2CC(OC(C3=CC=CC=C3)C4=CC=CC=C4)C[C@@H]1CC2.CS(=O)(O)=O

Molecular Formula

C22H29NO4S

Molecular Weight

403.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Santosh S Kulkarni, et al. Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H (1) receptors. Bioorg Med Chem. 2006 Jun 1;14 (11) :3625-34.|[2]Jihong Cui, et al. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget. 2017 Jan 3;8 (1) :1007-1022.